D
David E. Griffith
Researcher at University of Texas Health Science Center at Tyler
Publications - 204
Citations - 15827
David E. Griffith is an academic researcher from University of Texas Health Science Center at Tyler. The author has contributed to research in topics: Nontuberculous mycobacteria & Mycobacterium abscessus. The author has an hindex of 56, co-authored 194 publications receiving 13356 citations. Previous affiliations of David E. Griffith include University of Texas at Austin & Ouachita Baptist University.
Papers
More filters
Journal ArticleDOI
An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.
David E. Griffith,Timothy R. Aksamit,Barbara A. Brown-Elliott,Antonino Catanzaro,Charles L. Daley,Fred M. Gordin,Steven M. Holland,Robert Horsburgh,Gwen A. Huitt,Michael F. Iademarco,Michael D. Iseman,Kenneth N. Olivier,Stephen J. Ruoss,C. Fordham von Reyn,Richard J. Wallace,Kevin L. Winthrop +15 more
TL;DR: Diagnostic Criteria of Nontuberculous Mycobacterial Lung Disease Key Laboratory Features of N TM Health Careand Hygiene-associated Disease Prevention Prophylaxis and Treatment of NTM Disease Introduction Methods.
Journal ArticleDOI
Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients
TL;DR: Although the disease was generally slowly progressive, 21 of 154 patients died as a consequence of progressive RGM lung disease and respiratory failure, RGM should be recognized as a cause of chronic mycobacterial lung disease, and respiratory isolates should be assessed carefully.
Journal ArticleDOI
Elevated levels of NAP-1/interleukin-8 are present in the airspaces of patients with the adult respiratory distress syndrome and are associated with increased mortality.
E. J. Miller,Allen B. Cohen,S. Nagao,David E. Griffith,Richard Maunder,Terry Martin,J. P. Weiner-Kronish,M. Sticherling,E. Christophers,Michael A. Matthay +9 more
TL;DR: The data established that NAP-1/IL-8 is an important neutrophil chemotaxin in the airspaces of patients with ARDS, and those patients with very high concentrations of NAP/il-8 in their bronchoalveolar lavage fluids had a higher mortality rate than those patientswith lower concentrations.
Journal ArticleDOI
Nosocomial outbreaks/pseudo-outbreaks caused by nontuberculous mycobacteria.
TL;DR: Knowledge of the reservoir of these species, their great survival capabilities within the hospital, and newer molecular techniques for strain comparison have helped control and more quickly identify current nosocomial outbreaks or pseudo-outbreaks caused by the NTM.
Journal ArticleDOI
Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.
Charles L. Daley,Jonathan M. Iaccarino,Christoph Lange,Emmanuelle Cambau,Richard J. Wallace,Claire Andrejak,Erik C. Böttger,Jan Brozek,David E. Griffith,Lorenzo Guglielmetti,Lorenzo Guglielmetti,Gwen A. Huitt,Shandra L Knight,Philip Leitman,Theodore K. Marras,Kenneth N. Olivier,Miguel Santin,Jason E. Stout,Enrico Tortoli,Jakko van Ingen,Dirk Wagner,Kevin L. Winthrop +21 more
TL;DR: This guideline focuses on pulmonary disease in adults (without cystic fibrosis or human immunodeficiency virus infection) caused by the most common NTM pathogens such as Mycobacterium avium complex, MycOBacterium kansasii, and Myc Cobacterium xenopi among the slowly growing NTM and MyCobacterius abscessus among the rapidly growing N TM.